{
    "clinical_study": {
        "@rank": "87201", 
        "arm_group": [
            {
                "arm_group_label": "golimumab", 
                "arm_group_type": "Active Comparator", 
                "description": "golimumab 50mg subcutaneous every 4 weeks"
            }, 
            {
                "arm_group_label": "pamidronate", 
                "arm_group_type": "Active Comparator", 
                "description": "Pamidronate (60mg) intravenously every 4 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the efficacy of golimumab with pamidronate in the treatment of axial\n      spondyloarthropathy"
        }, 
        "brief_title": "Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Spondyloarthropathy", 
        "condition_browse": {
            "mesh_term": "Spondylarthropathies"
        }, 
        "detailed_description": {
            "textblock": "To compare the efficacy of golimumab with pamidronate in the treatment of non-radiological\n      axial spondyloarthropathy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects greater than 18 years of age\n\n          2. Fulfilling the latest classification criteria for axial spondyloarthropathy\n\n          3. Active spondylitis as defined by a Bath Ankylosing Spondylitis Disease Activity Index\n             (BASDAI) score of more than 4 despite treatment with non-steroid anti-inflammatory\n             drugs for more than 3 months\n\n        Exclusion Criteria:\n\n          1. Major surgery (including joint surgery) within 8 weeks prior to study entry\n\n          2. History of treatment with anti-tumor necrosis factor agents or any investigational\n             therapies within 12 months of study entry\n\n          3. Immunization with a live/attenuated vaccine within 4 weeks prior to study entry\n\n          4. Active current bacterial, viral, fungal, mycobacterial or other infections at study\n             entry\n\n          5. Chronic hepatitis B or hepatitis C carriers\n\n          6. History of malignancies, including solid tumors and hemic malignancies\n\n          7. History of congestive heart failure\n\n          8. History of demyelinating disorders\n\n          9. History of peripheral neuropathy\n\n         10. Pregnant women or lactating mothers\n\n         11. Baseline liver parenchymal enzymes elevated to more than 2 times normal\n\n         12. Absolute lymphocyte count less than 500/mm3\n\n         13. Serum creatinine level of more than 200umol/L"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718951", 
            "org_study_id": "CREC/769/09"
        }, 
        "intervention": [
            {
                "arm_group_label": "golimumab", 
                "description": "golimumab", 
                "intervention_name": "golimumab", 
                "intervention_type": "Drug", 
                "other_name": "Simponi"
            }, 
            {
                "arm_group_label": "pamidronate", 
                "description": "pamidronate", 
                "intervention_name": "Pamidronate", 
                "intervention_type": "Drug", 
                "other_name": "Aridia"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pamidronate"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "spondyloarthropathy", 
            "ankylosing spondylitis"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hong Kong", 
                    "country": "Hong Kong"
                }, 
                "name": "Tuen Mun Hospital"
            }
        }, 
        "location_countries": {
            "country": "Hong Kong"
        }, 
        "number_of_arms": "2", 
        "official_title": "Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Hong Kong: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Proportion of patients who achieve the Assessment of SpondyloArthritis international Society criteria (ASAS)-20 response", 
            "measure": "Assessment of SpondyloArthritis international Society criteria (ASAS)-20 response response", 
            "safety_issue": "No", 
            "time_frame": "week 48"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718951"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tuen Mun Hospital", 
            "investigator_full_name": "Chi Chiu Mok", 
            "investigator_title": "Consultant", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Changes in MRI spinal inflammation scores", 
            "measure": "Changes in MRI spinal inflammation scores", 
            "safety_issue": "No", 
            "time_frame": "week 24 and 48"
        }, 
        "source": "Tuen Mun Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tuen Mun Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}